Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)

Berufsverband der Augenärzte Deutschlands e. V.; Deutsche Ophthalmologische Gesellschaft; Retinologische Gesellschaft e. V.

doi:10.1055/a-0597-9563

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2018; 235(05): 626-637
DOI: 10.1055/a-0597-9563

Statement

Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)^[*]

Stand Januar 2018 Berufsverband der Augenärzte Deutschlands e. V., Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft e. V.

Abstract

Volltext

Referenzen

Literatur
1 Alkin Z, Osmanbasoglu OA, Ozkaya A. et al. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol 2013; 2: 96-101
2 Ayata A, Tatlipinar S, Kar T. et al. Near-infrared and short-wavelength autofluorescence imaging in central serous chorioretinopathy. Br J Ophthalmol 2009; 93: 79-82
3 Bae SH, Heo JW, Kim C. et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011; 152: 784-792.e2
4 Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina 2003; 23: 235-237
5 Bonini Filho MA, de Carlo TE, Ferrara D. et al. Association of choroidal neovascularization and central serous chorioretinopathy with optical coherence tomography angiography. JAMA Ophthalmol 2015; 133: 899-906
6 Bousquet E, Beydoun T, Rothschild PR. et al. Spironolactone for nonresolving central serous chorioretinopathy. Retina 2015; 35: 2505-2515
7 Bousquet E, Bonnin S, Mrejen S. et al. Optical coherence tomography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina 2018; 38: 629-638 doi:10.1097/IAE.0000000000001580
8 Bujarborua D. Long-term follow-up of idiopathic central serous chorioretinopathy without laser. Acta Ophthalmol Scand 2001; 79: 417-421
9 Bujarborua D, Chatterjee S, Choudhury A. et al. Fluorescein angiographic features of asymptomatic eyes in central serous chorioretinopathy. Retina 2005; 25: 422-429
10 Bujarborua D, Nagpal PN, Deka M. Smokestack leak in central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2010; 248: 339-351
11 Caccavale A, Romanazzi F, Imparato M. et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol 2010; 4: 899-903
12 Chan WM, Lam DSC, Lai TYY. et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-1458
13 Chan WM, Lai TYY, Lai RYK. et al. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008; 115: 1756-1765
14 Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 2017; 37: 325-333
15 Chong CF, Yang D, Pham TQ. et al. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep 2012;
16 Chuang EL, Sharp DM, Fitzke FW. et al. Retinal dysfunction in central serous retinopathy. Eye (Lond) 1987; 1: 120-125
17 Chung YR, Seo EJ, Lew HM. et al. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye 2013; 27: 1339-1346
18 Daruich A, Matet A, Dirani A. et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 2015; 48: 82 doi:10.1016/j.preteyeres.2015.05.003
19 Daruich A, Matet A, Marchionno L. et al. Acute central serous chorioretinopathy: factors influencing episode duration. Retina 2017; 37: 1905 doi:10.1097/IAE.0000000000001443
20 Delori FC, Dorey CK, Staurenghi G. et al. In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36: 718-729
21 Desai UR, Alhalel AA, Campen TJ. et al. Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003; 95: 553-559
22 Elsner H, Pörksen E, Klatt C. et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006; 244: 1638-1645
23 Ficker L, Vafidis G, While A. et al. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988; 72: 829-834
24 Forooghian F, Meleth AD, Cukras C. et al. Finasteride for chronic central serous chorioretinopathy. Retina 2011; 31: 766-771
25 French DD, Margo CE. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study. Retina 2010; 30: 271-274
26 Gäckle HC, Lang GE, Freissler KA. et al. Central serous chorioretinopathy. Clinical, fluorescein angiography and demographic aspects. Ophthalmologe 1998; 95: 529-533
27 de Gasparo M, Joss U, Ramjoué HP. et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656
28 Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology 1995; 102: 737-747
29 Gilbert CM, Owens SL, Smith PD. et al. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984; 68: 815-820
30 Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003; 110: 698-703
31 Heinrich MR. Central serous retinopathy and alpha-blockaders. Bull Soc Ophtalmol Fr 1974; 74: 681-683
32 Iacono P, Battaglia PM, Papayannis A. et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol 2015; 253: 1889-1897
33 Iida T, Yannuzzi LA, Spaide RF. et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003; 23: 1-7 quiz 137–8
34 Jain AK, Kaines A, Schwartz S. Bilateral central serous chorioretinopathy resolving rapidly with treatment for obstructive sleep apnea. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1037-1039
35 de Jong EK, Breukink MB, Schellevis RL. et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 2015; 122: 562-570
36 Katsimpris JM, Pournaras CJ, Sehgelmeble CW. et al. Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 2007; 245: 460-463
37 Kitaya N, Nagaoka T, Hikichi T. et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003; 87: 709-712
38 Kitzmann AS, Pulido JS, Diehl NN. et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; 115: 169-173
39 Klatt C, Saeger M, Oppermann T. et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 2011; 95: 83-88
40 Lai TYY, Staurenghi G, Lanzetta P. et al. MINERVA Study Group. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: twelve-month results of the MINERVA study. Retina 2017;
41 Lainscak M, Pelliccia F, Rosano G. et al. Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Int J Cardiol 2015; 200: 25-29
42 Lavinsky D, Sramek C, Wang J. et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina 2014; 34: 87-97
43 Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979; 63: 674-677
44 Lee H, Lee J, Chung H. et al. Baseline spectral domain optical coherence tomographic hyperreflective foci as a predictor of visual outcome and recurrence for central serous chorioretinopathy. Retina 2016; 36: 1372-1380
45 Lim JI, Spee C, Hinton DR. A comparison of hypoxia-inducible factor-alpha in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients. Retina 2010; 30: 1472-1478
46 Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics 1971; 12: 398-401
47 Liu B, Deng T, Zhang J. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina 2016; 36: 9-19
48 Ma J, Meng N, Xu X. et al. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol 2014; 92: e594-e601
49 Maruko I, Iida T, Sugano Y. et al. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010; 117: 1792-1799
50 Matet A, Daruich A, Zola M. et al. Risk factors for recurrences of central serous chorioretinopathy. Retina 2017;
51 Matsumoto H, Kishi S, Otani T. et al. Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008; 145: 162-168
52 Meyerle CB, Freund KB, Bhatnagar P. et al. Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina 2007; 27: 943-946
53 Nicholson B, Noble J, Forooghian F. et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58: 103-126
54 Nicholson BP, Atchison E, Idris AA. et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 2017; 63: 1-8 doi:10.1016/j.survophthal.2017.06.008
55 Nicolò M, Zoli D, Musolino M. et al. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 2012; 153: 474-480.e1
56 Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina 2011; 31: 1928-1936
57 OʼKeefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008; 10: 492-497
58 Peiretti E, Ferrara DC, Caminiti G. et al. Choroidal neovascularization in caucasian patients with longstanding central serous chorioretinopathy. Retina 2015; 35: 1360-1367
59 Piccolino FC, De La Longrais RR, Manea M. et al. Posterior cystoid retinal degeneration in central serous chorioretinopathy. Retina 2008; 28: 1008-1012
60 Pichi F, Carrai P, Ciardella A. et al. Central Serous Chorioretinopathy Study Group. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol 2016; 37: 1115 doi:10.1007/s10792-016-0377-2
61 Pikkel J, Beiran I, Ophir A. et al. Acetazolamide for central serous retinopathy. Ophthalmology 2002; 109: 1723-1725
62 Pitt B, Bakris G, Ruilope LM. et al. Investigators EPHESUS. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643-1650
63 Quaranta-El Maftouhi M, El Maftouhi A, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol 2015; 160: 581-587.e1
64 Rahbani-Nobar MB, Javadzadeh A, Ghojazadeh L. et al. The effect of helicobacter pylori treatment on remission of idiopathic central serous chorioretinopathy. Mol Vis 2011; 17: 99-103
65 Rahimy E, Pitcher JD, Hsu J. et al. A randomized double-blind placebo-control pilot study of eplerenone for the treatment of central serous chorioretinopathy (ecselsior). Retina 2017;
66 Reibaldi M, Cardascia N, Longo A. et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010; 149: 307-315.e2
67 Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983; 95: 457-466
68 Roider J, Brinkmann R, Wirbelauer C. et al. Subthreshold (RPE) photocoagulation in macular diseases – a pilot study. Br J Ophthalmol 2000; 84: 40-47
69 Salehi M, Wenick AS, Law HA. et al. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev 2015; (12) CD011841
70 Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 2017; 34: 1528-1555
71 Schubert C, Pryds A, Zeng S. et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat 2014; 35: 859-867
72 Schwartz R, Habot-Wilner Z, Martinez MR. et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol 2017; 95: e610 doi:10.1111/aos.13491
73 Senturk F, Karacorlu M, Ozdemir H. et al. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011; 151: 303-309.e1
74 Sharma T, Shah N, Rao M. et al. Visual outcome after discontinuation of corticosteroids in atypical severe central serous chorioretinopathy. Ophthalmology 2004; 111: 1708-1714
75 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011; 31: 1937-1943
76 Shinojima A, Hirose T, Mori R. et al. Morphologic findings in acute central serous chorioretinopathy using spectral domain-optical coherence tomography with simultaneous angiography. Retina 2010; 30: 193-202
77 Shinojima A, Sawa M, Sekiryu T. et al. A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. Ophthalmologica 2017; 237: 159-166 doi:10.1159/000455807
78 Shulman S, Goldenberg D, Schwartz R. et al. Oral rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2016; 254: 15-22
79 Spaide RF, Klancnik JM. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005; 112: 825-833
80 Spaide RF, Campeas L, Haas A. et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996; 103: 2070-2079
81 Spaide RF, Hall L, Haas A. et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996; 16: 203-213
82 Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986; 224: 321-324
83 Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P. et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int J Ophthalmol 2014; 7: 350-354
84 Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 2015; 99: 1070-1077 doi:10.1136/bjophthalmol-2014-305353
85 Vasconcelos H, Marques I, Santos AR. et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2013; 251: 1697-1705 doi:10.1007/s00417-013-2270-2
86 Verma L, Sinha R, Venkatesh P. et al. Comparative evaluation of diode laser versus argon laser photocoagulation in patients with central serous retinopathy: a pilot, randomized controlled trial [ISRCTN84128484]. BMC Ophthalmol 2004; 4: 15
87 Wolfensberger TJ, Chiang RK, Takeuchi A. et al. Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 2000; 238: 76-80
88 Wong R, Chopdar A, Brown M. Five to 15 year follow-up of resolved idiopathic central serous chorioretinopathy. Eye 2004; 18: 262-268
89 Wood EH, Karth PA, Sanislo SR. et al. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: what is the evidence?. Retina 2017; 37: 1021-1033
90 Wu ZHY, Lai RYK, Yip YWY. et al. Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. Retina 2011; 31: 1378-1386
91 Yalcinbayir O, Gelisken O, Akova-Budak B. et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina 2014; 34: 705-712
92 Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc 1986; 84: 799-845
93 Yannuzzi LA, Shakin JL, Fisher YL. et al. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984; 91: 1554-1572

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)[*]

Stellungnahme des Berufsverbandes der Augenärzte Deutschlands, der Deutschen Ophthalmologischen Gesellschaft und der Retinologischen Gesellschaft zur Chorioretinopathia centralis serosa (CCS)^[*]